Brought to you by 
Novartis divests Sandoz's US generics businesses to Aurobindo for up to $1bn; deal later terminated
25 Aug 2022
Executive Summary
Aurobindo Pharma Ltd.'s Aurobindo Pharma USA Inc. agreed to buy certain portions of Sandoz International GMBH's US Sandoz's US generic dermatology and US generic oral solids businesses, which parent Novartis AG is divesting.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Topical Delivery
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis divests Sandoz's US generics businesses to Aurobindo for up to $1bn; deal later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice